Merck & Co., Inc.(MRK)
2Q25 Earnings First Take: Headline Beat But Complicated Outlook(Buy)
2Q Earnings Preview: Expect A Noisy Print Amid Depressed Sentiment; Focus Will Be On The 2H Event Path(Buy)
